Biowaiver monographs for immediate release solid oral dosage forms: lamivudine.
暂无分享,去创建一个
D. Barends | H. Junginger | S. Stavchansky | K. Midha | V. Shah | J. Dressman | E. Jantratid | S. Kopp | S. Strauch
[1] D. Barends,et al. Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. , 2011, Journal of pharmaceutical sciences.
[2] Leslie Z Benet,et al. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. , 2010, Basic & clinical pharmacology & toxicology.
[3] B. Clotet,et al. Transport of Lamivudine [(-)-β-l-2′,3′-Dideoxy-3′-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3 , 2009, Journal of Pharmacology and Experimental Therapeutics.
[4] B. Lämmle,et al. Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation , 2009, British journal of haematology.
[5] J. Polli. In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms , 2008, The AAPS Journal.
[6] Bharti Sapra,et al. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine , 2007, AAPS PharmSciTech.
[7] R. Saha,et al. Design and study of lamivudine oral controlled release tablets , 2007, AAPS PharmSciTech.
[8] P. N. Raju,et al. Solubility and Dissolution Rate Determination of Different Antiretroviral Drugs in Different pH Media Using UV Visible Spectrophotometer , 2008 .
[9] Saranjit Singh,et al. Gastrointestinal permeability studies using combinations of rifampicin and nucleoside analogue reverse transcriptase inhibitors in rats , 2007 .
[10] T. Monif,et al. Comparative bioavailability/bioequivalence of two different stavudine 40 mg capsule formulations: a randomized, 2-way, crossover study in healthy volunteers under fasting condition. , 2007, International journal of clinical pharmacology and therapeutics.
[11] S. Swaminathan,et al. Can Urine Lamivudine Be Used to Monitor Antiretroviral Treatment Adherence? , 2006, MedGenMed : Medscape general medicine.
[12] C. Fernandes,et al. Dissolution test for lamivudine tablets: optimization and statistical analysis. , 2006, Journal of pharmaceutical and biomedical analysis.
[13] Jonathan A C Sterne,et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis , 2006, The Lancet.
[14] S. Rohani,et al. Polymorphic Behavior and Crystal Habit of an Anti-Viral/HIV Drug: Stavudine , 2006 .
[15] V. Porta,et al. Determination of lamivudine in human plasma by HPLC and its use in bioequivalence studies. , 2005, International journal of pharmaceutics.
[16] G. Malhotra,et al. Pharmacokinetic Profiling and Bioequivalence Evaluation of 2 Lamivudine Tablet Formulations After Single Oral Administration in Healthy Human Indian Volunteers , 2005, Journal of acquired immune deficiency syndromes.
[17] J. Sterne,et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. , 2005, Archives of internal medicine.
[18] G. Malhotra,et al. Bioequivalence evaluation of two marketed brands of stavudine 40 mg capsules in healthy human South African volunteers. , 2004, Pharmacological research.
[19] G. Wortmann,et al. Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). , 2004, Psychosomatics.
[20] Jennifer B Dressman,et al. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[21] C. Farthing,et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] G L Amidon,et al. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. , 2004, Journal of pharmaceutical sciences.
[23] Henrike Potthast,et al. Biopharmaceutical characterization of sotalol-containing oral immediate release drug products. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[24] Mei-Ling Chen,et al. Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. , 2004, Journal of pharmaceutical sciences.
[25] G. Amidon,et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. , 2004, Molecular pharmaceutics.
[26] D. Hoelscher,et al. Equivalent Steady-State Pharmacokinetics of Lamivudine in Plasma and Lamivudine Triphosphate within Cells following Administration of Lamivudine at 300 Milligrams Once Daily and 150 Milligrams Twice Daily , 2004, Antimicrobial Agents and Chemotherapy.
[27] Hitoshi Sezaki,et al. Analysis of Drug Permeation Across Caco-2 Monolayer: Implication for Predicting In Vivo Drug Absorption , 1997, Pharmaceutical Research.
[28] Malcolm Rowland,et al. Comparison of HT29-18-C1 and Caco-2 Cell Lines as Models for Studying Intestinal Paracellular Drug Absorption , 1996, Pharmaceutical Research.
[29] P. Statkevich,et al. Renal Disposition and Drug Interaction Screening of (–)-2′-deoxy-3′-thiacytidine (3TC) in the Isolated Perfused Rat Kidney , 1995, Pharmaceutical Research.
[30] S. Yamashita,et al. Characterization of Drug Transport Through Tight-Junctional Pathway in Caco-2 Monolayer: Comparison with Isolated Rat Jejunum and Colon , 1995, Pharmaceutical Research.
[31] Per Artursson,et al. Selective Paracellular Permeability in Two Models of Intestinal Absorption: Cultured Monolayers of Human Intestinal Epithelial Cells and Rat Intestinal Segments , 1993, Pharmaceutical Research.
[32] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[33] M. Gumbleton,et al. Stereoselective and Concentration-Dependent Polarized Epithelial Permeability of a Series of Phosphoramidate Triester Prodrugs of d4T: An in Vitro Study in Caco-2 and Madin-Darby Canine Kidney Cell Monolayers , 2003, Journal of Pharmacology and Experimental Therapeutics.
[34] S. A. Thomas,et al. Effect of Transport Inhibitors and Additional Anti-HIV Drugs on the Movement of Lamivudine (3TC) across the Guinea Pig Brain Barriers , 2003, Journal of Pharmacology and Experimental Therapeutics.
[35] L. Szczech,et al. Steady-State Pharmacokinetics of Lamivudine in Human Immunodeficiency Virus-Infected Patients with End-Stage Renal Disease Receiving Chronic Dialysis , 2002, Antimicrobial Agents and Chemotherapy.
[36] D. Grasela,et al. Pharmacokinetics of Single-Dose Oral Stavudine in Subjects with Renal Impairment and in Subjects Requiring Hemodialysis , 2000, Antimicrobial Agents and Chemotherapy.
[37] R. Perrone,et al. Pharmaceutical relationships of three solid state forms of stavudine. , 2000, International journal of pharmaceutics.
[38] Myron S. Cohen,et al. Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.
[39] Sinko,et al. Involvement of multiple transporters in the oral absorption of nucleoside analogues. , 1999, Advanced drug delivery reviews.
[40] P. Artursson,et al. A conditionally immortalized epithelial cell line for studies of intestinal drug transport. , 1999, The Journal of pharmacology and experimental therapeutics.
[41] A. D. Clark,et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[42] J. Eron,et al. Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1 , 1999, Antimicrobial Agents and Chemotherapy.
[43] Sean C. Sweetman,et al. Martindale: The Complete Drug Reference , 1999 .
[44] A. D. Clark,et al. Sarafianos, S.G. et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with -branched amino acids. Proc. Natl. Acad. Sci. USA 96, 10027-10032 , 1999 .
[45] G. E. Pakes,et al. Clinical Pharmacokinetics of Lamivudine , 1999, Clinical pharmacokinetics.
[46] P. Harrigan,et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. , 1998, The Journal of infectious diseases.
[47] S. Kaul,et al. Effect of Food on the Bioavailability of Stavudine in Subjects with Human Immunodeficiency Virus Infection , 1998, Antimicrobial Agents and Chemotherapy.
[48] S. A. Thomas,et al. The transport of the anti‐HIV drug, 2′,3′‐didehydro‐3′‐deoxythymidine (D4T), across the blood‐brain and blood‐cerebrospinal fluid barriers , 1998, British journal of pharmacology.
[49] J. Horák,et al. PHARMACOKINETICS AND DISPOSITION , 1998 .
[50] D. Grasela,et al. Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment , 1997, Antimicrobial agents and chemotherapy.
[51] M. Dudley,et al. Clinical Pharmacokinetics of Stavudine , 1997, Clinical pharmacokinetics.
[52] C. Perry,et al. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. , 1997, Drugs.
[53] A. Cross,et al. Clinical Efficacy of Monotherapy with Stavudine Compared with Zidovudine in HIV-Infected, Zidovudine-Experienced Patients , 1997, Annals of Internal Medicine.
[54] B. Gazzard,et al. The role of stavudine in the management of adults with HIV infection. , 1997, Antiviral therapy.
[55] P. Sinko,et al. Oral absorption of anti-acquired immune deficiency syndrome nucleoside analogues. 2. Carrier-mediated intestinal transport of stavudine in rat and rabbit preparations. , 1996, Journal of pharmaceutical sciences.
[56] J. Eron,et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim‐sulfamethoxazole , 1996, Clinical pharmacology and therapeutics.
[57] D. Faulds,et al. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. , 1996, Drugs.
[58] M. Saneyoshi,et al. Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats. , 1996, Biological & pharmaceutical bulletin.
[59] N. Nguyen,et al. Solubility behavior of lamivudine crystal forms in recrystallization solvents. , 1996, Journal of pharmaceutical sciences.
[60] E. Hussey,et al. Pharmacokinetics, Absolute Bioavailability, and Absorption Characteristics of Lamivudine , 1995, Journal of clinical pharmacology.
[61] M. Swartz. Mitochondrial toxicity--new adverse drug effects. , 1995, The New England journal of medicine.
[62] K. Squires,et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex , 1995, Antimicrobial agents and chemotherapy.
[63] J. Montaner,et al. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.
[64] R. Tubiana,et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. , 1995, The Journal of infectious diseases.
[65] A. Cross,et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. , 1995, The Journal of infectious diseases.
[66] G. Skowron. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. , 1995, The Journal of infectious diseases.
[67] S. Kaul,et al. Dose proportionality of stavudine in hiv seropositive asymptomatic subjects: Application to bioequivalence assessment of various capsule formulations , 1995, Biopharmaceutics & drug disposition.
[68] S. Steinberg,et al. 2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. , 1993, The Journal of infectious diseases.
[69] S. Danner,et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a Phase I study , 1992, AIDS.
[70] R. Schinazi,et al. Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells. , 1992, Biochemical pharmacology.
[71] V. Skalski,et al. Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. , 1992, The Journal of biological chemistry.
[72] J. Cameron,et al. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5'-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma , 1992, Antimicrobial Agents and Chemotherapy.
[73] J. Cameron,et al. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro , 1992, Antimicrobial Agents and Chemotherapy.
[74] M. Wainberg,et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog , 1991, Antimicrobial Agents and Chemotherapy.
[75] P. Artursson,et al. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.
[76] J. Starrett,et al. 1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine. A Highly Potent and Selective Anti-HIV Agent. , 1989 .
[77] E. De Clercq,et al. Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. , 1989, The Journal of biological chemistry.
[78] W. Prusoff,et al. Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus. , 1988, Biochemical pharmacology.
[79] C. Goodman. United States Pharmacopeial Convention , 1988 .
[80] J Desmyter,et al. Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. , 1987, Biochemical and biophysical research communications.
[81] W. Thomson. The International Pharmacopoeia. , 1952, The Practitioner.
[82] Van Os. [The international pharmacopeia]. , 1951, Pharmaceutisch weekblad.